Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Provided By PR Newswire
Last update: Dec 27, 2024
CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024.
Read more at prnewswire.com
